PT  - JOURNAL ARTICLE
AU  - Samuel E. Jones
AU  - Fahrisa I. Maisha
AU  - Satu J. Strausz
AU  - Brian E. Cade
AU  - Anniina M. Tervi
AU  - Viola Helaakoski
AU  - Martin E. Broberg
AU  - Vilma Lammi
AU  - FinnGen
AU  - Jacqueline M. Lane
AU  - Susan Redline
AU  - Richa Saxena
AU  - Hanna M. Ollila
TI  - The public health impact of poor sleep on severe COVID-19, influenza and upper respiratory infections
AID  - 10.1101/2022.02.16.22271055
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.16.22271055
4099  - http://medrxiv.org/content/early/2022/02/17/2022.02.16.22271055.short
4100  - http://medrxiv.org/content/early/2022/02/17/2022.02.16.22271055.full
AB  - Background Poor sleep is associated with an increased risk of infections and all-cause mortality, and acute sleep loss and disruption have been linked with inflammation and poorer immune control. Previous studies, however, have been unable to evidence causality between the chronic effects of poor sleep and respiratory infection risk. In light of the ongoing COVID-19 pandemic and potential future disease outbreaks, understanding the risk factors for these infections is of great importance.Aim Our goal was to understand if chronic poor sleep could be identified as a causal risk factor for respiratory infections including influenza, upper respiratory infections and COVID-19.Methods We used population cohorts from the UK Biobank (N ≈ 231,000) and FinnGen (N ≈ 327,000) with ICD-10 based electronic health records and obtained diagnoses of insomnia, influenza and upper respiratory infections (URIs) from primary care and hospital settings. We computed logistic regression to assess association between poor sleep and infections, disease free survival hazard ratios, and used summary statistics from genome-wide association studies of insomnia, influenza, URI and COVID-19 to perform Mendelian randomization analyses and assess causality.Findings Utilizing 23 years of registry data and follow-up, we saw that insomnia diagnosis associated with increased risk for infections in FinnGen and in UK Biobank (FinnGen influenza HR = 5.32 [4.09, 6.92], P = 1.02×10−35, UK Biobank influenza HR = 1.54 [1.37, 1.73], P = 2.49×10−13). Mendelian randomization indicated that insomnia causally predisposed to influenza (OR = 1.59, P = 6.23×10−4), upper respiratory infections (OR = 1.71, P = 7.60×10−13), COVID-19 infection (OR = 1.08, P = 0.037) and risk of hospitalization from COVID-19 (OR = 1.47, P = 4.96×10−5).Conclusions Our findings indicate that chronic poor sleep is a causal risk factor for contracting respiratory infections, and in addition contributes to the severity of respiratory infections. These findings highlight the role of sleep in maintaining sufficient immune response against pathogens as suggested by earlier work. As the current COVID-19 pandemic has increased the number of people suffering from poor sleep, safe interventions such as sleep management and treating individuals with insomnia could be promoted to reduce infections and save lives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHMO has received funding from the Instrumentarium Science Foundation and the Academy of Finland (award number 340539) and both HMO and AMT were supported by the Signe and Ane Gyllenberg foundation. JML was supported by NIH K01HL136884.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Individual-level data can be accessed on successful application to FinnGen and the UK Biobank cohorts. For FinnGen, applications for individual-level data can be made through the Finnish Biobanks' "FinnBB" portal (https://finbb.fi/) and summary GWA data, including for the influenza and URI phenotypes, can be accessed through the FinnGen website (https://www.finngen.fi/en/access_results). For the UK Biobank, applications for individual-level data can be made through the UK Biobank portal at https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes